Autolus (AUTL) Reports Obe-cel Launch Progress and Strong Cash Position in Q2 2024
Autolus Therapeutics plc (AUTL), a leader in T-cell therapies, announced its Q2 2024 financial results and business updates.…
FDA Clears CEL-SCI’s Multikine Study for Head and Neck Cancer
CEL-SCI Corporation (CVM), a leader in immunotherapy, announced FDA approval of its patient selection strategy for the upcoming…
Aethlon (AEMD) Reports Q1 2024 Results and Advances Cancer and Virus Treatment Trials
Aethlon Medical, Inc. (AEMD), a pioneering company in cancer and infectious disease therapies, has reported its fiscal Q1…
Treace Medical (TMCI) Reports 11% Revenue Growth in Q3 2024
Treace Medical Concepts, Inc. (TMCI), a leading innovator in the medical technology space focused on bunion treatment, announced…
Taysha Gene (TSHA) Reports Strong Q2 2024 Results and Advances TSHA-102 Trials
Taysha Gene Therapies, Inc. (TSHA), a leader in developing AAV-based gene therapies for severe central nervous system diseases,…
CEL-SCI’s Multikine Immunotherapy Boosts 5-Year Survival Rate in Head and Neck Cancer
CEL-SCI Corporation (NYSE American: CVM) has announced new breakthrough data from its Phase 3 trial of Multikine®, an…
Novartis Pioneers RNA Therapeutics with Borealis Biosciences for Kidney Diseases
Introduction In a groundbreaking move for the biotech industry, Novartis has partnered with Versant Ventures to establish Borealis…
Genentech’s Strategic Pivot: The Closure of Its Cancer Immunology Unit
Introduction In a significant and somewhat unexpected move within the biotech industry, Genentech, a subsidiary of Roche, has…
Breakthrough in Alzheimer’s Treatment: Biogen and Eisai’s Leqembi Wins UK Approval
Introduction The landscape of Alzheimer’s disease treatment has undergone a monumental shift with the UK’s Medicines and Healthcare…
Vera Therapeutics’ Atacicept Shows Promising Results in Phase 2b ORIGIN Trial for IgA Nephropathy
Vera Therapeutics has announced positive results from their Phase 2b ORIGIN clinical trial for atacicept, a novel investigational…
Ozempic Shows Lower Risk of Kidney and Heart Complications in Diabetic Patients
In a groundbreaking development, Novo Nordisk’s Ozempic (semaglutide) has demonstrated significant benefits in reducing the risk of kidney…
Eli Lilly Announces Historic $5.3 Billion Investment to Expand Indiana Manufacturing for Diabetes and Weight Loss Drugs
Expansion to Create 900 Permanent Jobs and Meet Rising Demand for Mounjaro and Zepbound Eli Lilly and Company…
Guardant Health’s Shield Blood Test for Colorectal Cancer Receives FDA Advisory Panel Endorsement
Guardant Health, a prominent player in precision oncology, has taken a significant step forward with its Shield blood…
Coherus Presents Promising Phase I Results for Anti-CCR8 Antibody CHS-114 at ASCO 2024
Coherus BioSciences has announced preliminary results from its Phase I dose-escalation study of CHS-114, an anti-CCR8 antibody, at…
Myriad Genetics Unveils Groundbreaking Cancer Care Innovations at ASCO 2024
Myriad Genetics has once again solidified its position at the forefront of precision medicine and genetic testing with…
Biogen Expands Immunology Portfolio with Strategic Acquisition
Biogen Inc. has announced the acquisition of Human Immunology Biosciences (HI-Bio) for an upfront payment of $1.15 billion,…
Takeda Inks Licensing Deal with Degron Therapeutics for Molecular Glue Degraders
Takeda Pharmaceuticals has announced an exclusive licensing agreement with Degron Therapeutics, a Chinese biotech company, to develop novel…
FDA Approves Biosimilars Yesafili and Opuviz, Opening New Avenues for Affordable Eye Treatments
The FDA has recently approved two new biosimilars, Yesafili (aflibercept-jbvf) by Biocon Biologics and Opuviz (aflibercept-yszy) by Samsung…